Document is current

Article History

Received: 26 February 2025

Accepted: 25 April 2025

First Online: 10 June 2025

Declarations

:

: Prof. Anastasios-Georgios Konstas: research funding from Allergan, Bayer, Omni Vision, Pharmathen, and Santen Pharmaceuticals Co., Inc; travel support and congress expenses from Vianex and Zwitter; and honoraria from Allergan, Esteve Pharmaceuticals, Santen, Inc., and Vianex. Dr. Bogomil Voykov: grants from Aerie Pharmaceuticals Ireland Ltd. and Santen Pharmaceuticals Co., Inc.; and speaker honorarium and consultancy fees from AbbVie Deutschland GmbH & Co. KG, Santen GmbH, and Novartis GmbH. Dr. Jan Lübke: received honoraria from Allergan/AbbVie; speaker honorarium and consulting fees from AbbVie Deutschland GmbH & Co. KG and Santen GmbH; and speaker honorarium from Glaukos, iStar medical, and Théa Pharma. Dr. Gerhard Garhöfer: consultant for Apis, Boehringer Ingelheim, Croma, EyeD, Kiora, Novaliq, Panoptes, Redwood, Santen Pharmaceuticals Co., Inc., Sintetica, and Thea. Dr. Auli Ropo: an employee of Santen, Oy.

: The study was conducted in compliance with regulatory requirements provided by the following institutional review boards or independent ethics committees; the Faculty of Medicine at the Eberhard-Karls-University and the University Hospital Tübingen (reference number 193/2021), Ethics Committee of the University of Freiburg and the University of Vienna (reference number 1229/2021), Ethics Committee for the Province of Salzburg, and the Hellenic Republic Ministry of Health National Ethics Committee (reference number 34443/2021), in accordance with the protocol, Good Clinical Practice, The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use International guidelines, and the Declaration of Helsinki. All participants provided written informed consent prior to their participation.